Garrett Nichols

2.9k total citations · 2 hit papers
28 papers, 1.8k citations indexed

About

Garrett Nichols is a scholar working on Epidemiology, Infectious Diseases and Genetics. According to data from OpenAlex, Garrett Nichols has authored 28 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 10 papers in Infectious Diseases and 9 papers in Genetics. Recurrent topics in Garrett Nichols's work include Virus-based gene therapy research (9 papers), Cytomegalovirus and herpesvirus research (9 papers) and HIV Research and Treatment (8 papers). Garrett Nichols is often cited by papers focused on Virus-based gene therapy research (9 papers), Cytomegalovirus and herpesvirus research (9 papers) and HIV Research and Treatment (8 papers). Garrett Nichols collaborates with scholars based in United States, United Kingdom and France. Garrett Nichols's co-authors include Michael Boeckh, Hans H. Hirsch, Filip Josephson, Andreas Pikis, Per Ljungman, Jens Lundgren, Veronica Miller, Raymund R. Razonable, Paul Griffiths and Brian Wynne and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Garrett Nichols

27 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

2016 693 citations Per Ljungman, Michael Boeckh et al. Clinical Infectious Diseases profile →
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

2013 593 citations Sharon Walmsley, Antonio Antela et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Garrett Nichols

Since Specialization

Citations

This map shows the geographic impact of Garrett Nichols's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Garrett Nichols with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Garrett Nichols more than expected).

Fields of papers citing papers by Garrett Nichols

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Garrett Nichols. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Garrett Nichols. The network helps show where Garrett Nichols may publish in the future.

Co-authorship network of co-authors of Garrett Nichols

This figure shows the co-authorship network connecting the top 25 collaborators of Garrett Nichols. A scholar is included among the top collaborators of Garrett Nichols based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Garrett Nichols. Garrett Nichols is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma. 2021 ·Journal of Clinical Oncology ·Andrew E. Sloan, Robin Buerki, Christopher Murphy, Andrea Kelly, Prakash Ambady, Michael C. Brown, Nicholas Butowski, Robert Cavaliere, William T. Curry, Annick Desjardins, (unknown), Henry S. Friedman, Matthias Gromeier, (unknown), Lori Mixson, Shirley Ong, Dina Randazzo, Patrick Y. Wen, Garrett Nichols	11
2	Abstract CT242: LUMINOS-103: A basket trial evaluating the safety and efficacy of PVSRIPO in patients with advanced solid tumors 2021 ·Cancer Research ·Brant A. Inman, Arjun Vasant Balar, Matthew I. Milowsky, Raj S. Pruthi, (unknown), Shannon R. Morris, Lori Mixson, (unknown), Elizabeth M. H. Woodson, Andrea Kelly, Garrett Nichols	2
3	Safety and efficacy of murine PVSRIPO plus anti-PD-1 immune checkpoint inhibitor (ICI) in a melanoma tumor model. 2021 ·Journal of Clinical Oncology ·(unknown), (unknown), Matthias Gromeier, Garrett Nichols, Andrea Kelly, Daniel Corum, Michael C. Brown	1
4	Practice patterns and incidence of adenovirus infection in allogeneic hematopoietic cell transplant recipients: Multicenter survey of transplant centers in the United States 2020 ·Transplant Infectious Disease ·Genovefa A. Papanicolaou, Christopher C. Dvorak, Sanjeet Dadwal, Gabriela Marón, Vinod K. Prasad, Roger Giller, Hisham Abdel‐Azim, Arhanti Sadanand, Roman Casciano, Aastha Chandak, (unknown), Garrett Nichols, (unknown), Enrikas Vainorius, Essy Mozaffari, Robert H. Hutcheson	10
5	Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study 2019 ·Bone Marrow Transplantation ·Marco Zecca, Robert Wynn, Jean‐Hugues Dalle, Tobias Feuchtinger, Enrikas Vainorius, Thomas M. Brundage, Aastha Chandak, Essy Mozaffari, Garrett Nichols, Franco Locatelli	26
6	Brincidofovir Decreases Adenovirus Viral Burden, Which is Associated with Improved Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients 2018 ·Biology of Blood and Marrow Transplantation ·Thomas M. Brundage, Enrikas Vainorius, Greg Chittick, Garrett Nichols	2
7	Incidence of Adenovirus Infection in Hematopoietic Stem Cell Transplantation Recipients: Findings from the AdVance Study 2018 ·Biology of Blood and Marrow Transplantation ·Petr Sedláček, (unknown), Marie Robin, Ponni Sivaprakasam, Enrikas Vainorius, (unknown), Aastha Chandak, Essy Mozaffari, Garrett Nichols, Sebastian Voigt	43
8	The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality 2017 ·Blood ·Joshua A. Hill, Bryan T. Mayer, Hu Xie, Wendy M. Leisenring, Meei‐Li Huang, Terry Stevens‐Ayers, Filippo Milano, Colleen Delaney, Mohamed L. Sorror, Brenda M. Sandmaier, Garrett Nichols, Danielle M. Zerr, Keith R. Jerome, Joshua T. Schiffer, Michael Boeckh	120
9	Treatment of Adenovirus (AdV) Infection in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients (pts) with Brincidofovir: Final 36 Week Results from the Advise Trial 2017 ·Biology of Blood and Marrow Transplantation ·Vinod K. Prasad, Genovefa A. Papanicolaou, Gabriela Marón, Enrikas Vainorius, Thomas M. Brundage, Greg Chittick, Garrett Nichols, Michael Grimley	13
10	Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1. breakdown → 2016 ·Clinical Infectious Diseases ·Per Ljungman, Michael Boeckh, Hans H. Hirsch, Filip Josephson, Jens Lundgren, Garrett Nichols, Andreas Pikis, Raymund R. Razonable, Veronica Miller, Paul Griffiths	693
11	Detection of Multiple Double-Stranded DNA Viruses after Cord Blood Transplantation Is Frequent and Persistent 2015 ·Blood ·Joshua A. Hill, Bryan T. Mayer, Hu Xie, Wendy M. Leisenring, Filippo Milano, Colleen Delaney, Meei‐Li Huang, Terry Stevens‐Ayers, Keith R. Jerome, Garrett Nichols, Danielle M. Zerr, Joshua T. Schiffer, Michael Boeckh	1
12	48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis 2014 ·PLoS ONE ·Dipen Patel, Sonya J. Snedecor, (unknown), Lavanya Sudharshan, Jessica Lim, Robert L. Cuffe, Sonia Pulgar, Kim Gilchrist, (unknown), Jennifer Stephens, Garrett Nichols	68
13	Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients 2014 ·HIV Clinical Trials ·Lloyd Curtis, Garrett Nichols, (unknown), Jessica Lim, (unknown), Brian Wynne, Andrew Clark, Mark Bloch, Gudrun Maechler, (unknown), François Raffi, Sherene Min	34
14	Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection breakdown → 2013 ·New England Journal of Medicine ·Sharon Walmsley, Antonio Antela, Nathan Clumeck, Dan Duiculescu, (unknown), Félix Gutiérrez, Laurent Hocqueloux, Franco Maggiolo, Uriel Sandkovsky, Catherine Granier, Keith A. Pappa, Brian Wynne, Sherene Min, Garrett Nichols	593
15	“Clo’es could do de like o’ dat”: Race, Place, and Power in Mark Twain’s The Tragedy of Pudd’nhead Wilson 2013 ·The Southern literary journal ·Garrett Nichols	1
16	Assessing a Theoretical Risk of Dolutegravir-Induced Developmental Immunotoxicity in Juvenile Rats 2012 ·Toxicological Sciences ·Melissa C. Rhodes, Susan Laffan, (unknown), (unknown), Curtis C. Maier, Tamio Fukushima, Garrett Nichols, (unknown)	10
17	PK/PD modeling supports the dose-escalation decision in VIKING 2010 ·Journal of the International AIDS Society ·Mark Lovern, Mark Underwood, Garrett Nichols, Ivy Song	0
18	Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment 2009 ·Antimicrobial Agents and Chemotherapy ·Maria Jesús Pérez‐Elías, (unknown), Enrique Ortega, José Hernández‐Quero, M. Rodríguez‐Torres, Bonaventura Clotet, Franco Felizarta, Félix Gutiérrez, Juan A. Pineda, Garrett Nichols, Yu Lou, Mary Beth Wire	10
19	Auxotonic contractions in cardiac muscle segments 1979 ·American Journal of Physiology-Heart and Circulatory Physiology ·L. L. Huntsman, (unknown), (unknown), Garrett Nichols	14
20	A Low-Cost High-Gain Amplifier with Exceptional Noise Performance 1971 ·IEEE Transactions on Biomedical Engineering ·L. L. Huntsman, Garrett Nichols	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact